Introduction
============

Lung cancer is the leading cause of cancer-related mortality worldwide.[@b1-ott-12-1413] Of all lung cancer cases, 80--85% are non-small-cell lung cancers (NSCLC), and the majority of these cases are in advanced or metastatic stage (III or IV) at the time of diagnosis.[@b2-ott-12-1413],[@b3-ott-12-1413] Among these patients with NSCLC, a substantial number are harboring activating EGFR mutations, ranging from 10% in Europe to 38.4% in Asia.[@b4-ott-12-1413],[@b5-ott-12-1413] During the past years, targeted therapies including tyrosine kinase inhibitors (TKIs) have been developed and have become standard first-line treatment for patients with EGFR mutation-positive NSCLC.[@b6-ott-12-1413]--[@b8-ott-12-1413] Various trials showed higher response rates and improved progression-free survival (PFS) for first-line treatment with afatinib, erlotinib, and gefitinib compared to platinum-based doublet therapy in patients with activating EGFR-mutated (exon 19 deletion or exon 21 L858R mutation) NSCLC.[@b9-ott-12-1413]--[@b18-ott-12-1413] Recently, in head-to-head trials, dacomitinib and osimertinib showed a significant longer PFS compared to standard EGFR-TKIs, while dacomitinib, a second-generation EGFR-TKI, had a better efficacy compared to gefitinib, and osimertinib showed a more favorable PFS compared to standard EGFR-TKI (gefitinib or erlotinib).[@b19-ott-12-1413],[@b20-ott-12-1413] Different EGFR-TKIs are available for the treatment of patients with EGFR mutation-positive NSCLC. However, since sufficient data from head-to-head trials of all these EGFR-TKIs are lacking, evidence of relative efficacy and toxicity of these first-line TKIs is also scarce. Therefore, a network meta-analysis (NMA) was performed to compare the efficacy and toxicity of these TKIs as first-line treatment for patients with EGFR mutation-positive NSCLC. In traditional meta-analyses, the same intervention is compared to the same comparator in all included studies. NMA combines direct comparisons of interventions within randomized controlled trials (RCTs) with indirect comparisons across RCTs in multiple pairwise comparisons across a range of interventions. A greater share of available evidence is produced by using the NMA method compared to traditional meta-analysis. The NMA method enables judicious estimation of the relative treatment effect for comparative effectiveness purposes.[@b21-ott-12-1413] Previously published NMAs did not show significant differences between EGFR-TKIs.[@b22-ott-12-1413]--[@b26-ott-12-1413] New data for several (new) TKIs are available (ARCHER1050 and FLAURA trials),[@b19-ott-12-1413],[@b20-ott-12-1413] which may lead to new insights into the relative efficacy and toxicity of the EGFR-TKIs.

This study aimed to compare the efficacy and toxicity of first-line treatment with gefitinib, erlotinib, afatinib, dacomitinib, and osimertinib for patients with activating EGFR-mutated (exon 19 deletion or exon 21 L858R mutation) NSCLC by conducting an NMA of all available evidence in the literature.

Materials and methods
=====================

Search strategy and selection criteria
--------------------------------------

An electronic search of the PubMed, EMBASE, and Cochrane Library databases was conducted in order to find eligible studies for the NMA, following PRISMA guidelines.[@b27-ott-12-1413] Eligible studies were Phase IIB/III RCTs that compared the efficacy and toxicity of a single TKI to another TKI or to standard chemotherapy as first-line treatments in patients with stage IIIB/IV NSCLC harboring EGFR mutations and in patients who were not eligible for surgery or radiotherapy. Standard chemotherapy was defined as platinum-based doublet therapy.

Papers published from 1 January, 2010 up to and including 1 November, 2016 were included. Literature was reviewed by two reviewers (MSH and CAUG) and discrepancies were discussed. The selection of studies was based on inclusion and exclusion criteria. Details of the search strategy can be found in [Appendix A](#SD1-ott-12-1413){ref-type="supplementary-material"}. Reference lists of published systematic reviews and meta-analyses were checked to ensure that no studies were overlooked. In February 2018, the literature search was manually updated to ensure that no relevant studies were missing, as new trials have been published in the previous 2 years.

Data extraction and quality assessment
--------------------------------------

Information on study design, number of participants, patient characteristics, interventions, comparators, objective response rate (ORR) (complete or partial response according to RECIST v1.1), PFS (time from randomization until disease progression according to RECIST v1.1 or death from any cause), overall survival (OS) (time from randomization until death from any cause), and adverse events (AEs) were extracted. Toxicity was scored according to the Common Toxicity Criteria (CTC).[@b28-ott-12-1413] Absolute numbers of AEs were extracted and ORs were calculated. Diarrhea and rash (CTC grade 3 or higher) were included in the analyses of this study because these are the most common TKI-related AEs. Other AEs were not included in the final analysis because they are less impacting and are known to be relatively homogenous across all EGFR-TKIs.[@b29-ott-12-1413],[@b30-ott-12-1413] Data extraction was verified by the second reviewer (CAUG). For studies with more than one publication, the data were compared between publications. The most updated results were included in this study. Extracted data can be found in [Appendix B](#SD2-ott-12-1413){ref-type="supplementary-material"}.

Quality and risk of bias of the RCTs were assessed by using the Cochrane Collaboration's tool for assessing risk of bias.[@b31-ott-12-1413]

Statistical analyses
--------------------

We performed a Bayesian fixed-effects NMA in WinBUGS 1.4 by using an adapted version of WinBUGS code from Dias et al[@b32-ott-12-1413] ([Appendix C](#SD3-ott-12-1413){ref-type="supplementary-material"}). Due to the limited number of trials in each specific TKI group, a fixed-effects framework was deemed appropriate for the NMA.[@b33-ott-12-1413]--[@b35-ott-12-1413] The outcomes of PFS, OS, ORR, and AEs within trials were linked in a network.

To obtain the HR of treatment a vs b, the following formula was used for all comparisons: *HR*~a,b~ = (*e*^(^*^∂^*^b-^*^∂^*^a)^), and chemotherapy was used as the reference treatment in the network (*∂ chemo* = 0). All other *∂*'s were calculated based on direct and indirect evidence from the RCTs. The NMA also enabled us to estimate the probability of being the best treatment and to rank the treatments based on these probabilities. Brooks--Gelman--Rubin diagnostic with WinBUGS was used to assess convergence, which enabled the determination of the number of burn-in simulations that should be discarded before calculating the converged results.[@b36-ott-12-1413]

The FLAURA trial compared osimertinib with gefitinib or erlotinib. In this trial, no separate HRs of osimertinib vs gefitinib or osimertinib vs erlotinib were reported. Therefore, we assumed that the HRs of PFS and OS were the same for osimertinib vs gefitinib as they were for osimertinib vs erlotinib.

Results
=======

Identification of studies and study quality
-------------------------------------------

Electronic search in the databases resulted in 6,182 records, from which 4,664 internal and external duplicates were excluded. Three additional records were included after a manual update of the literature search. After screening the titles and abstracts of the remaining 1,521 records, 66 abstracts and manuscripts were eligible for full-text reading. After this, 53 records were excluded and 13 unique RCTs were included in the analyses. The flow chart is presented in [Figure 1](#f1-ott-12-1413){ref-type="fig"}.

The patient characteristics of the 13 RCTs are summarized in [Table 1](#t1-ott-12-1413){ref-type="table"}. Eight of the 13 RCTs studied gefitinib (NEJ002, WJTOG3405, IPASS, First-SIGNAL, Lux-Lung 6, CTONG0901, ARCHER1050, and FLAURA).[@b9-ott-12-1413]--[@b12-ott-12-1413],[@b14-ott-12-1413],[@b19-ott-12-1413],[@b20-ott-12-1413],[@b37-ott-12-1413]--[@b41-ott-12-1413] Four RCTs studied erlotinib (OPTIMAL, EURTAC, ENSURE, and CTONG0901),[@b13-ott-12-1413],[@b15-ott-12-1413],[@b18-ott-12-1413],[@b40-ott-12-1413],[@b42-ott-12-1413] three studied afatinib (Lux-Lung 3, Lux-Lung 6, and Lux-Lung 7),[@b16-ott-12-1413],[@b17-ott-12-1413],[@b39-ott-12-1413],[@b43-ott-12-1413],[@b44-ott-12-1413] and one trial was included in the analyses for both dacomitinib and osimertinib (the ARCHER1050 and FLAURA study, respectively).[@b19-ott-12-1413],[@b20-ott-12-1413] Due to the heterogeneous study population of the IPASS and First-SIGNAL trials, we only included the results of the patients with activating EGFR-mutated (exon 19 deletion or exon 21 L858R mutation) NSCLC. A total of 3,539 patients with EGFR mutation-positive NSCLC were available for analyses, 2,691 of whom were randomly assigned to a TKI-arm and 848 of whom received platinum-based doublet therapy. The HRs for PFS and OS, as reported in the trials, are presented in [Table 2](#t2-ott-12-1413){ref-type="table"}. All 13 RCTs were classified as having acceptable quality and low risk of bias, according to the Cochrane Collaboration's tool ([Appendix D](#SD4-ott-12-1413){ref-type="supplementary-material"}).

Network meta-analysis
---------------------

[Figure 2](#f2-ott-12-1413){ref-type="fig"} shows the complete network, which comprised 13 RCTs that studied a TKI compared to another TKI or chemotherapy in patients with EGFR-mutated NSCLC. We simulated three different chains, which produced 60,000 iterations each. Due to a burn-in period, 30,000 iterations were discarded in each chain; the results were based on a total sample of 90,000 iterations. Brooks--Gelman--Rubin plots showed convergence of the parameters.

[Table 3](#t3-ott-12-1413){ref-type="table"}, [Figure 3](#f3-ott-12-1413){ref-type="fig"}, and [Figures S1--S6](#SD1-ott-12-1413){ref-type="supplementary-material"} in [Appendix E](#SD5-ott-12-1413){ref-type="supplementary-material"} present the NMA results for PFS, OS, ORR, and AEs (diarrhea and rash). Osimertinib showed a significantly better PFS and OS compared to all other TKIs. It also had the highest probability of 99% and 85%, thus showing the longest PFS and OS, respectively, as compared to other TKIs. Dacomitinib also showed a significantly improved PFS compared to gefitinib, erlotinib, and afatinib. Furthermore, afatinib and osimertinib performed best in terms of ORR compared to all other drugs with a probability of 46% for both drugs. However, the distribution of probabilities of being the best did not differ significantly on ORR ([Figure 3](#f3-ott-12-1413){ref-type="fig"}).

Diarrhea occurred significantly more often in patients treated with afatinib or dacomitinib. Gefitinib, erlotinib, and osimertinib showed a mild risk of diarrhea and chemotherapy had a low risk, with probabilities of being the best for diarrhea, with 7%, 6%, 15%, and 72%, respectively. Regarding rash, occurrence was high among patients treated with afatinib or dacomitinib and moderate among patients treated with gefitinib, erlotinib, or osimertinib. The risk of rash was low for chemotherapy with 99% probability of being the best treatment.

Discussion
==========

In patients with EGFR-mutated NSCLC, TKIs have shown superior efficacy compared to platinum-based doublet therapy.[@b10-ott-12-1413]--[@b18-ott-12-1413] Now that we have at least five different EGFR-TKIs, the relative efficacy and toxicity of these TKIs become important to help physicians choose the optimal drug for treatment. In contrast to meta-analysis, which only estimates the relative effect of the same interventions with the same comparators, an NMA combines direct evidence within RCTs with indirect evidence across RCTs to estimate the relative effect of multiple pairwise comparisons. In this way, the relative efficacy of a whole set of treatments for a disease can be synthesized.[@b21-ott-12-1413] Previous NMAs tried to provide relative evidence on the efficacy of EGFR-TKIs by using only three or four TKIs, or by including both first- and second-line TKIs in the network. These studies did not show significant differences between EGFR-TKIs in terms of efficacy and toxicity. Since a number of head-to-head trials between these drugs and data from new EGFR-TKIs are now available, we performed an NMA with five different TKIs (afatinib, dacomitinib, erlotinib, gefitinib, and osimertinib) to estimate their relative efficacy and toxicity as first-line treatment in patients with EGFR-mutated (exon 19 deletion or exon 21 L858R mutation) NSCLC. The results of the NMA indicated that osimertinib was significantly more effective on PFS compared to all other drugs. Dacomitinib proved to be the second best TKI effective on PFS with a significantly better PFS compared to gefitinib, erlotinib, and afatinib. Osimertinib also showed a significantly better efficacy in terms of OS compared to all other TKIs. Furthermore, AEs (diarrhea and rash) occurred more often in patients treated with afatinib or dacomitinib, compared to the other treatments. Due to the limited number of trials per treatment arm, a fixed-effect NMA was considered appropriate because heterogeneity could not be appropriately assessed.[@b33-ott-12-1413]--[@b35-ott-12-1413]

To our knowledge, this is the first study that performed an NMA to compare the results between five first-line EGFR-TKIs. Previous NMA studies failed to show significant differences between EGFR-TKIs.[@b22-ott-12-1413]--[@b26-ott-12-1413] By including additional evidence from new RCTs[@b19-ott-12-1413],[@b20-ott-12-1413],[@b40-ott-12-1413] and updating results in the network, new results were produced, namely significant efficacy differences between the TKIs.

An important assumption in our study was that all included studies were generally similar, both clinically and methodologically. All 13 studies included only patients with activating EGFR mutations, with the percentage of males ranging from 11% to 47%, the median age range being 56--65 years, and the percentage of adenocarcinoma histology type ranging between 90% and 100% across the studies, which contributed to the homogeneity of the study population. Additionally, efficacy of EGFR-TKIs could be different when it was provided as second- or third-line treatment. A previous study showed that chemotherapy might change the proportion of tumor cells with EGFR mutations within the primary tumor.[@b45-ott-12-1413] Treatment with a TKI after platinum-based doublet therapy would thus probably affect the efficacy by inducing resistance mechanisms. Therefore, only first-line TKI treatments were included in our analyses in order to avoid such bias and to improve homogeneity.

For our analysis, the most common NMA method was used and, consequently, proportional hazards were assumed.[@b32-ott-12-1413] Since in eleven of the 13 trials the proportional hazard assumption could be checked, the assumption was not violated.

The length of follow-up differed among the included studies. As HRs may depend on the follow-up period, findings may vary when HRs are estimated at a different followup period. Due to a lack of patient-level data, correction for the different lengths of follow-up in an NMA is not possible. Insight into the long-term direction of HRs can be obtained with a longer follow-up duration, although this will also induce selection bias.[@b46-ott-12-1413]

Although osimertinib showed a significant better OS compared to all drugs, gefitinib, erlotinib, and afatinib did not reveal a significant effect on OS compared to chemotherapy, which was similar to the individual studies. Some individual studies even showed OS results which were in favor of chemotherapy due to high proportions of crossover in the chemotherapy arms.[@b9-ott-12-1413],[@b11-ott-12-1413],[@b13-ott-12-1413]--[@b15-ott-12-1413] The minimum proportion of crossover in the chemotherapy arm was 59.3% in the WJTOG3405 study[@b11-ott-12-1413] and the maximum was 94.6% in the NEJ002 study.[@b10-ott-12-1413] A much smaller proportion of patients in whom TKI was initiated received chemotherapy as subsequent treatment.[@b10-ott-12-1413],[@b11-ott-12-1413],[@b13-ott-12-1413]--[@b17-ott-12-1413] A recent study suggested that patients who received chemotherapy or TKI after first-line TKI or first-line chemotherapy had a longer OS than patients who only received first-line therapy.[@b42-ott-12-1413] The imbalanced subsequent treatments of the TKI and chemotherapy arms may have resulted in no significant OS differences between TKIs and chemotherapy. Therefore, it is questionable whether OS is an appropriate outcome measure in studies with substantial crossover.

Since final OS data were not available during our study period, the OS data of the FLAURA study were based on an interim analysis. Although this analysis did not show a formal statistical significance for OS, osimertinib seems to show a potential survival benefit compared to standard TKI.[@b20-ott-12-1413] An update of our NMA is desirable when final OS data of the FLAURA trial become available.

Conclusion
==========

Our study showed that osimertinib is the most favorable EGFR-TKI in terms of PFS and OS. With regard to AEs, afatinib and dacomitinib had a higher risk of diarrhea and rash. Gefitinib, erlotinib, and osimertinib showed a mild risk of AEs. Thus, regarding its high efficacy and mild toxicity pattern, osimertinib is indicated as the most favorable first-line TKI in patients with activating EGFR-mutated (exon 19 deletion or exon 21 L858R mutation) NSCLC.
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![Flow chart of the selection of studies.\
**Abbreviations:** RCT, randomized controlled trial; NSCLC, non-small-cell lung cancer.](ott-12-1413Fig1){#f1-ott-12-1413}

![Complete network based on 13 RCTs. **Abbreviation:** RCT, randomized controlled trial.](ott-12-1413Fig2){#f2-ott-12-1413}

![Distribution of probabilities of being the best for outcomes and two major toxicities, classified by drugs.\
**Note:** \**P*\<0.0001.\
**Abbreviations:** ORR, objective response rate; OS, overall survival; PFS, progression- free survival.](ott-12-1413Fig3){#f3-ott-12-1413}

###### 

Characteristics of included studies regarding TKIs

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Trial                                                Treatment      EGFR patients   Male (%)   Age                                                Ethnicity   Never/previous or current smoker (%)   Adenocarcinoma histology (%)
  ---------------------------------------------------- -------------- --------------- ---------- -------------------------------------------------- ----------- -------------------------------------- ------------------------------
  NEJ002[@b10-ott-12-1413]                             Gefitinib\     114\            37\        63.9[a](#tfn1-ott-12-1413){ref-type="table-fn"}\   Japanese\   66/34\                                 90\
                                                       TC             114             36         62.6[a](#tfn1-ott-12-1413){ref-type="table-fn"}    Japanese    58/42                                  97

  WJTOG3405[@b11-ott-12-1413]                          Gefitinib\     86\             31\        64[b](#tfn2-ott-12-1413){ref-type="table-fn"}\     Japanese\   71/29\                                 97\
                                                       DP             86              30         64[b](#tfn2-ott-12-1413){ref-type="table-fn"}      Japanese    66/34                                  98

  IPASS[@b12-ott-12-1413] (Fukuoka et al. 2011)        Gefitinib\     132\            21\        57[b](#tfn2-ott-12-1413){ref-type="table-fn"}\     Asian\      94/6\                                  95\
                                                       TC             129             21         57[b](#tfn2-ott-12-1413){ref-type="table-fn"}      Asian       94/6                                   97

  First-SIGNAL[@b14-ott-12-1413] (Han et al. 2012)     Gefitinib\     26\             12\        57[b](#tfn2-ott-12-1413){ref-type="table-fn"}\     Korean\     N/A\                                   N/A\
                                                       GP             16              11         56.5[b](#tfn2-ott-12-1413){ref-type="table-fn"}    Korean      N/A                                    N/A

  OPTIMAL[@b13-ott-12-1413] (Zhou et al. 2011)         Erlotinib\     82\             41\        57[b](#tfn2-ott-12-1413){ref-type="table-fn"}\     Asian\      72/28\                                 88\
                                                       GC             72              40         59[b](#tfn2-ott-12-1413){ref-type="table-fn"}      Asian       69/31                                  86

  EURTAC[@b15-ott-12-1413] (Rosell et al. 2012)        Erlotinib\     86\             33\        65[b](#tfn2-ott-12-1413){ref-type="table-fn"}\     European\   66/34\                                 95\
                                                       CT             87              22         65[b](#tfn2-ott-12-1413){ref-type="table-fn"}      European    72/28                                  90

  ENSURE[@b18-ott-12-1413] (Wu et al. 2015)            Erlotinib\     110\            38         57.5[b](#tfn2-ott-12-1413){ref-type="table-fn"}\   Asian\      72/28\                                 95\
                                                       GC             107                        56[b](#tfn2-ott-12-1413){ref-type="table-fn"}      Asian       69/31                                  94

  Lux-Lung 3[@b16-ott-12-1413] (Sequist et al. 2013)   Afatinib\      230\            36\        61.5[b](#tfn2-ott-12-1413){ref-type="table-fn"}\   Global\     67/33\                                 100\
                                                       AP             115             33         61[b](#tfn2-ott-12-1413){ref-type="table-fn"}      Global      70/30                                  100

  Lux-Lung 6[@b17-ott-12-1413] (Wu et al. 2014)        Afatinib\      242\            36\        58[b](#tfn2-ott-12-1413){ref-type="table-fn"}\     Asian\      75/25\                                 100\
                                                       GP             122             32         58[b](#tfn2-ott-12-1413){ref-type="table-fn"}      Asian       81/19                                  100

  Lux-Lung 7[@b39-ott-12-1413] (Park et al. 2016)      Afatinib\      160\            43\        63[b](#tfn2-ott-12-1413){ref-type="table-fn"}\     Global\     66/34\                                 99\
                                                       Gefitinib      159             33         63[b](#tfn2-ott-12-1413){ref-type="table-fn"}      Global      67/33                                  99

  CTONG0901[@b40-ott-12-1413] (Yang et al. 2017)       Erlotinib\     128\            47\        [c](#tfn3-ott-12-1413){ref-type="table-fn"}        N/A\        82/18\                                 96\
                                                       Gefitinib      128             46                                                            N/A         73/27                                  96

  ARCHER1050[@b19-ott-12-1413] (Wu et al. 2017)        Dacomitinib\   227\            36\        62[b](#tfn2-ott-12-1413){ref-type="table-fn"}\     Global\     65/26\                                 N/A\
                                                       Gefitinib      225             44         61[b](#tfn2-ott-12-1413){ref-type="table-fn"}      Global      64/36                                  N/A

  FLAURA[@b20-ott-12-1413] (Soria et al. 2018)         Osimertinib\   279\            36\        64[b](#tfn2-ott-12-1413){ref-type="table-fn"}\     Global\     65/35\                                 99\
                                                       Standard\      277             38         64[b](#tfn2-ott-12-1413){ref-type="table-fn"}      Global      63/37                                  98
                                                       TKI                                                                                                                                             
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Mean;

median;

in gefitinib arm, 72 patients (56.3%) were ≤60 years and 56 patients (43.8%) were \>60 years old, and in erlotinib arm, 71 patients (55.5%) were ≤60 years and 57 patients (44.5%) were \>60 years.

**Abbreviations:** TKI, tyrosine kinase inhibitor; EGFR, epidermal growth factor receptor; AP, cisplatin+pemetrexed; CT, chemotherapy (not specific); DP, cisplatin+docetaxel; GC, carboplatin+gemcitabine; GP, cisplatin+gemcitabine; TC, carboplatin+paclitaxel; N/A, not available.

###### 

HRs for PFS and OS of randomized studies in patients with EGFR-mutated advanced NSCLC treated with TKIs

  Trial                                                                                             Treatment     Control        Primary end point   HR (95% CI)            
  ------------------------------------------------------------------------------------------------- ------------- -------------- ------------------- ---------------------- ----------------------
                                                                                                                                                                            
  NEJ002[a](#tfn5-ott-12-1413){ref-type="table-fn"},[@b10-ott-12-1413] (Maemondo et al. 2010)       Gefitinib     TC             PFS                 0.30 (0.22--0.41)      0.887 (0.634--1.241)
  WJTOG3405[a](#tfn5-ott-12-1413){ref-type="table-fn"},[@b11-ott-12-1413] (Mitsudomi et al. 2010)   Gefitinib     DP             PFS                 0.489 (0.336--0.710)   1.252 (0.883--1.775)
  IPASS[a](#tfn5-ott-12-1413){ref-type="table-fn"},[@b12-ott-12-1413] (Fukuoka et al. 2011)         Gefitinib     TC             OS                  0.48 (0.36--0.64)      1.00 (0.76--1.33)
  First-SIGNAL[a](#tfn5-ott-12-1413){ref-type="table-fn"},[@b14-ott-12-1413] (Han et al. 2012)      Gefitinib     GP             OS                  0.544 (0.269--1.1)     1.043 (0.498--2.182)
  OPTIMAL[a](#tfn5-ott-12-1413){ref-type="table-fn"},[@b13-ott-12-1413] (Zhou et al. 2011)          Erlotinib     GC             PFS                 0.16 (0.10--0.26)      1.19 (0.83--1.71)
  EURTAC[a](#tfn5-ott-12-1413){ref-type="table-fn"},[@b15-ott-12-1413] (Rosell et al. 2012)         Erlotinib     CT             PFS                 0.37 (0.25--0.54)      1.04 (0.65--1.68)
  ENSURE[a](#tfn5-ott-12-1413){ref-type="table-fn"},[@b18-ott-12-1413] (Wu et al. 2015)             Erlotinib     GC             PFS                 0.34 (0.22--0.51)      0.91 (0.63--1.31)
  Lux-Lung 3[a](#tfn5-ott-12-1413){ref-type="table-fn"},[@b16-ott-12-1413] (Sequist et al. 2013)    Afatinib      AP             PFS                 0.58 (0.43--0.78)      0.88 (0.66--1.17)
  Lux-Lung 6[a](#tfn5-ott-12-1413){ref-type="table-fn"},[@b17-ott-12-1413] (Wu et al. 2014)         Afatinib      GP             PFS                 0.28 (0.20--0.39)      0.93 (0.72--1.22)
  Lux-Lung 7[a](#tfn5-ott-12-1413){ref-type="table-fn"},[@b39-ott-12-1413] (Park et al. 2016)       Afatinib      Gefitinib      PFS, OS             0.73 (0.57--0.95)      0.86 (0.66--1.12)
  CTONG0901[@b40-ott-12-1413] (Yang et al. 2017)                                                    Erlotinib     Gefitinib      PFS                 0.96 (0.69--1.35)      0.98 (0.67--1.42)
  ARCHER1050[@b19-ott-12-1413] (Wu et al. 2017)                                                     Dacomitinib   Gefitinib      PFS                 0.59 (0.47--0.74)      0.76 (0.582--0.993)
  FLAURA[a](#tfn5-ott-12-1413){ref-type="table-fn"},[@b20-ott-12-1413] (Soria et al. 2018)          Osimertinib   Standard TKI   PFS                 0.46 (0.37--0.57)      0.63 (0.45--0.88)

**Note:**

Crossover was allowed after progression on first-line treatment.

**Abbreviations:** TKI, tyrosine kinase inhibitor; EGFR, epidermal growth factor receptor; NSCLC, non-small-cell lung cancer; PFS, progression-free survival; OS, overall survival; CT, chemotherapy (not specific); DP, cisplatin+docetaxel; GC, carboplatin+gemcitabine; GP, cisplatin+gemcitabine; N/A, not available; TC, carboplatin+paclitaxel; AP, cisplatin+pemetrexed.

###### 

Treatment comparisons for PFS, OS (HRs \[95% CI\]), ORR, diarrhea, and rash (ORs \[95% CI\])

  --------------------- -------------------- --------------------- --------------------- ------------------- ----------------------
  **PFS**                                                                                                    
  Chemotherapy          2.34 (2.03, 2.71)    2.76 (2.3, 3.34)      2.7 (2.27, 3.24)      3.95 (3.05, 5.21)   5.64 (4.58, 7.02)
  0.43 (0.37, 0.49)     Gefitinib            1.17 (0.98, 1.41)     1.15 (0.96, 1.39)     1.68 (1.35, 2.13)   2.4 (2, 2.91)
  0.36 (0.30, 0.43)     0.85 (0.71, 1.02)    Erlotinib             0.97 (0.77, 1.25)     1.42 (1.08, 1.93)   2.04 (1.7, 2.46)
  0.37 (0.31, 0.44)     0.87 (0.72, 1.04)    1.03 (0.8, 1.3)       Afatinib              1.45 (1.09, 1.97)   2.07 (1.62, 2.69)
  0.25 (0.19, 0.33)     0.59 (0.47, 0.74)    0.7 (0.52, 0.93)      0.69 (0.51, 0.91)     Dacomitinib         1.41 (1.06, 1.91)
  0.18 (0.14, 0.22)     0.42 (0.34, 0.5)     0.49 (0.41, 0.59)     0.48 (0.37, 0.62)     0.71 (0.52, 0.94)   Osimertinib
                                                                                                             
  **OS**                                                                                                     
  Chemotherapy          0.97 (0.84, 1.12)    0.99 (0.83, 1.19)     1.11 (0.94, 1.31)     1.26 (0.94, 1.73)   1.54 (1.19, 2.04)
  1.03 (0.89, 1.19)     Gefitinib            1.02 (0.84, 1.24)     1.14 (0.96, 1.38)     1.3 (1.01, 1.72)    1.59 (1.24, 2.07)
  1.01 (0.84, 1.21)     0.98 (0.80, 1.19)    Erlotinib             1.11 (0.89, 1.42)     1.27 (0.93, 1.8)    1.56 (1.22, 2.03)
  0.9 (0.76, 1.06)      0.88 (0.73, 1.05)    0.90 (0.71, 1.13)     Afatinib              1.13 (0.83, 1.59)   1.38 (1.04, 1.89)
  0.79 (0.58, 1.06)     0.77 (0.58, 0.99)    0.79 (0.56, 1.08)     0.88 (0.63, 1.21)     Dacomitinib         1.20 (0.84, 1.77)
  0.65 (0.49, 0.84)     0.63 (0.48, 0.81)    0.64 (0.49, 0.82)     0.72 (0.53, 0.96)     0.84 (0.57, 1.19)   Osimertinib
                                                                                                             
  **ORR**                                                                                                    
  Chemotherapy          0.26 (0.2, 0.34)     0.20 (0.14, 0.27)     0.16 (0.12, 0.22)     0.22 (0.16, 0.31)   0.16 (0.10, 0.27)
  3.86 (2.94, 5)        Gefitinib            0.75 (0.54, 1.08)     0.63 (0.46, 0.89)     0.84 (0.68, 1.04)   0.62 (0.4, 1.02)
  5.09 (3.66, 6.91)     1.33 (0.93, 1.86)    Erlotinib             0.82 (0.55, 1.27)     1.08 (0.74, 1.66)   0.82 (0.53, 1.34)
  6.08 (4.45, 8.1)      1.59 (1.13, 2.17)    1.22 (0.79, 1.81)     Afatinib              1.30 (0.9, 1.96)    0.97 (0.58, 1.73)
  4.60 (3.23, 6.37)     1.19 (0.96, 1.46)    0.92 (0.6, 1.35)      0.77 (0.51, 1.12)     Dacomitinib         0.73 (0.45, 1.26)
  6.18 (3.65, 9.8)      1.61 (0.98, 2.49)    1.23 (0.75, 1.9)      1.04 (0.58, 1.72)     1.37 (0.79, 2.2)    Osimertinib
                                                                                                             
  **Diarrhea**                                                                                               
  Chemotherapy          0.25 (0.08, 1.36)    0.2 (0.06, 1.32)      0.03 (0.01, 0.15)     0.02 (0, 0.25)      0.22 (0.06, 1.45)
  4 (0.74, 12.81)       Gefitinib            0.65 (0.21, 3.37)     0.08 (0.03, 0.37)     0.07 (0.02, 0.43)   0.79 (0.32, 2.67)
  5.11 (0.76, 17.91)    1.55 (0.3, 4.82)     Erlotinib             0.08 (0.02, 0.73)     0.07 (0.02, 0.91)   0.95 (0.38, 3.21)
  39.8 (6.71, 131.4)    12.01 (2.7, 35.35)   12.03 (1.38, 46.74)   Afatinib              0.59 (0.14, 6.84)   6.39 (1.82, 43.4)
  53.34 (3.96, 239.4)   13.36 (2.33, 44)     14.36 (1.1, 64.27)    1.71 (0.15, 7.28)     Dacomitinib         6.04 (1.52, 58.31)
  4.58 (0.69, 15.86)    1.26 (0.37, 3.16)    1.05 (0.31, 2.63)     0.16 (0.02, 0.55)     0.17 (0.02, 0.66)   Osimertinib
                                                                                                             
  **Rash**                                                                                                   
  Chemotherapy          0.23 (0.1, 0.71)     0.11 (0.04, 0.42)     0.06 (0.02, 0.22)     0 (0, 0.05)         0.08 (0.03, 0.35)
  4.28 (1.4, 10.23)     Gefitinib            0.41 (0.15, 1.6)      0.22 (0.10, 0.65)     0 (0, 0.16)         0.31 (0.12, 1.08)
  9.18 (2.39, 24.56)    2.46 (0.63, 6.74)    Erlotinib             0.39 (0.12, 2.21)     0.01 (0, 0.43)      0.63 (0.25, 2.18)
  18.06 (4.51, 49.39)   4.47 (1.54, 10.17)   2.57 (0.45, 8.35)     Afatinib              0.01 (0, 0.77)      1.11 (0.35, 5.86)
  1,170 (19.4, 7,267)   275.4 (6.1, 1,636)   162 (2.34, 1,009)     77.97 (1.31, 477.4)   Dacomitinib         11.15 (1.82, 740.19)
  12.94 (2.87, 37.81)   3.24 (0.92, 8.28)    1.59 (0.46, 4.03)     0.9 (0.17, 2.83)      0.09 (0, 0.55)      Osimertinib
  --------------------- -------------------- --------------------- --------------------- ------------------- ----------------------

**Abbreviations:** OS, overall survival; PFS, progression-free survival; ORR, objective response rate.
